Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
Article 2014 en
Authors
TA
Tadaaki Arizumi
KU
Kazuomi Ueshima
HT
Haruhiko Takeda
Abstract
1 min read
Only the use of the RECICL allowed for identification of a subgroup of HCC patients treated with sorafenib with improved prognosis. The RECICL should, therefore, be considered a superior system for assessment of therapeutic response.
Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Antonio Craxı̀, Peter R. Galle, Armando Santoro, Michel Beaugrand, Angelo Sangiovanni, Camillo Porta, Guido Gerken, Jorge A. Marrero, Andrea Nadel, Michael Shan, M. Moscovici, D. Voliotis, Josep M. Llovet
Jean-François H. Geschwind, Masatoshi Kudo, Jorge A. Marrero, Alan P. Venook, Xiao-Ping Chen, Jean-Pierre Bronowicki, Lucy Dagher, Junji Furuse, Laura Ladrón de Guevara, Christos N. Papandreou, Arun J. Sanyal, Tadatoshi Takayama, Sheng-Long Ye, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Riccardo Lencioni
Discussion(0)
No comments yet. Be the first to comment.